HDAC inhibitors are reported to be valuable in GBM therapyin preclinical phases, as they enhance tumor cell sensitivity to DNAalkylating chemotherapeutic agents through open chromatin conformationin tumor cells and help reverse abnormal genetic silencing in GBM,leading to the enhanced arrest of the cell cycle and apoptosis.520. The gene discussed is HDAC9; the disease is glioblastoma.